News

The study also did not meet its key secondary endpoints. Adverse events were generally balanced between Ace-ER and placebo and safety was consistent with previously released Ace-ER data.

Dravet Syndrome is a rare pediatric disease and lifelong form of epilepsy, which starts in the first year of life with frequent or prolonged seizures. Currently, the company

The results were reported by ViraCyte lead investigators at Baylor College of Medicine in the Journal of Clinical Oncology1.   Viralym-M is an "off-the-shelf", 3rd party T-cell product

Under the agreement, Grid has acquired the exclusive rights to all intellectual property, including relevant patents, related to Complement Factor H (CFH) antibodies as a cancer therapy, and

Both the compounds were discovered through the research collaboration between Zealand and Boehringer Ingelheim. According to Zealand, the glucagon/GLP-1 agonist activates two key gut hormone receptors GLP-1 and

Ibrance is an oral inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), which triggers cellular progression. Patina is a randomized, open-label and phase 3 clinical trial, which will assess

This marks the second program Ovid has advanced into Phase 2 clinical development this year. Takeda and Ovid formed a global collaboration focused on the clinical development and

Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking,

Under the deal, the partnership will develop new stabilised non-immunogenic modified RNA therapies (mRNA) for respiratory diseases by using Ethris’ SNIM RNA technology. As per terms of the